Lambert-Eaton myasthenic syndrome
| Lambert-Eaton Myasthenic Syndrome | |
 | |
|---|---|
| Global view of a neuromuscular junction: 1. Axon 2. Motor end-plate 3. Muscle fiber 4. Myofibril | |
| ICD-10 | G73.1 |
| ICD-9 | 358.1 |
| DiseasesDB | 4030 |
| MeSH | D015624 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Keanu Ngo[2] Synonyms and keywords: Eaton-Lambert syndrome; Lambert-Eaton syndrome; LEMS
Overview
Lambert-Eaton myasthenic syndrome (LEMS) is a rare, autoimmune disorder of the presynaptic neuromuscular junction caused by antibodies against P/Q-type (CaV2.1) voltage-gated calcium channels (VGCCs) on the motor nerve terminal. Antibody-mediated loss of functional VGCCs reduces depolarization-evoked calcium influx, lowering quantal release of acetylcholine so that endplate potentials fail to reach the threshold for muscle contraction — producing weakness.[1][2] LEMS presents with a clinical triad of proximal (leg-predominant) weakness, autonomic dysfunction, and hyporeflexia with post-activation facilitation. Diagnosis rests on the convergence of clinical features, electrophysiology, and serology. Because roughly half of cases are paraneoplastic — almost always small cell lung cancer (SCLC) — a new diagnosis mandates rigorous oncologic screening.[3][4]
Historical Perspective
- Anderson and colleagues first reported a case with clinical features consistent with LEMS in 1953.
- Lambert, Eaton, and Rooke provided the first substantial description of the clinical and electrophysiological features of the disorder in the mid-1950s to 1960s, establishing the characteristic incremental response to high-frequency repetitive nerve stimulation.[5]
- In 1989, the responsible antibodies were shown to be directed against presynaptic voltage-gated calcium channels, establishing the autoimmune, presynaptic basis of the disease.[1]
Classification
LEMS is classified by the presence or absence of an underlying malignancy:[2][3]
- Paraneoplastic (cancer-associated) LEMS — approximately 50–60% of cases, almost always small cell lung cancer (SCLC); rarely other tumors. The VGCC antigen expressed on tumor cells triggers the cross-reacting antibody response. Conversely, about 3–4% of unselected patients with SCLC are found to have LEMS.
- Non-tumor / idiopathic LEMS (NT-LEMS) — the remainder, associated with other autoimmunity and, in many patients, an HLA-B8-DR3 haplotype background.
Pathophysiology
LEMS is antibody-mediated. IgG autoantibodies against P/Q-type (CaV2.1) VGCCs on the motor nerve terminal cause antigenic modulation and loss of functional channels. The reduced calcium influx during depolarization decreases the number of acetylcholine quanta released per nerve impulse, so endplate potentials often fail to reach threshold — producing weakness that transiently improves after brief maximal exercise (post-activation facilitation) as intracellular calcium accumulates.[1][5]
- In paraneoplastic LEMS, SCLC cells express functional VGCCs; the antitumor immune response cross-reacts with neuronal VGCCs.
- In NT-LEMS, autoimmunity against P/Q-type VGCC arises without a tumor, frequently on an HLA-B8-DR3/DQ2 background.
Detailed molecular mechanisms are covered in the Pathophysiology microchapter.
Causes
LEMS is caused by autoantibodies against presynaptic P/Q-type VGCCs. The principal identifiable trigger is an underlying malignancy, most commonly small cell lung cancer; other tumors (non-SCLC, lymphoproliferative disorders, thymoma) are rarely implicated. Non-tumor cases are idiopathic autoimmune disorders often co-occurring with other autoimmune conditions.[2][3]
Differentiating Lambert-Eaton Myasthenic Syndrome from other Diseases
LEMS must be distinguished from myasthenia gravis and other causes of neuromuscular weakness. Unlike myasthenia gravis, LEMS is leg-predominant and proximal, only rarely causes isolated ocular weakness, and characteristically improves briefly with activity.[4][6]
| Diseases | History and Physical | Diagnostic tests | Other Findings | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Motor Deficit | Sensory deficit | Cranial nerve Involvement | Autonomic dysfunction | Proximal/Distal/Generalized | Ascending/Descending/Systemic | UL / BL / NL | Onset | Lab or Imaging Findings | Specific test | ||
| Adult Botulism | + | - | + | + | Generalized | Descending | BL | Sudden | Toxin test | Blood, Wound, or Stool culture | Diplopia, Hyporeflexia, Hypotonia, possible respiratory paralysis |
| Infant Botulism | + | - | + | + | Generalized | Descending | BL | Sudden | Toxin test | Blood, Wound, or Stool culture | Flaccid paralysis (Floppy baby syndrome), possible respiratory paralysis |
| Guillain-Barre syndrome[7] | + | - | - | - | Generalized | Ascending | BL | Insidious | CSF: ↑Protein, ↓Cells | Clinical & Lumbar Puncture | Progressive ascending paralysis following infection, possible respiratory paralysis |
| Lambert-Eaton syndrome[8] | + | - | + | + | Proximal (legs) | Systemic | BL | Insidious | EMG, repetitive nerve stimulation (RNS): low CMAP, decrement at low frequency, increment (>60%) after exercise | P/Q-type voltage gated calcium channel (VGCC) antibody | Proximal weakness, hyporeflexia, autonomic features; post-exercise facilitation. Strongly associated with SCLC |
| Myasthenia gravis[6] | + | - | + | - | Generalized (ocular/bulbar prominent) | Systemic | BL | Intermittent | EMG, RNS: decrement at low frequency (no facilitation) | AChR and MuSK antibody | Diplopia, ptosis, fatigable weakness worsening with activity |
| Electrolyte disturbance[9] | + | + | - | - | Generalized | Systemic | BL | Insidious | Electrolyte panel | ↓Ca++, ↓Mg++, ↓K+ | Possible arrhythmia |
| Organophosphate toxicity[10] | + | + | - | + | Generalized | Systemic | BL | Sudden | Clinical diagnosis; RBC AChE activity | ↓RBC/plasma cholinesterase | Exposure to insecticide; DUMBELS (Diarrhea, Urination, Miosis, Bradycardia, Emesis, Lacrimation, Salivation) |
| Tick paralysis[11] | + | - | - | - | Generalized | Ascending | BL | Insidious | Clinical diagnosis: physical exam & history | - | Outdoor exposure; tick often still attached (head/neck) |
| Tetrodotoxin poisoning[12] | + | - | + | + | Generalized | Systemic | BL | Sudden | Clinical diagnosis: physical exam & dietary history | - | Consumption of puffer fish species |
| Stroke[13] | +/- | +/- | +/- | +/- | Generalized | Systemic | UL | Sudden | MRI +ve for ischemia or hemorrhage | MRI | Sudden unilateral deficit with vascular risk factors or atrial fibrillation |
| Poliomyelitis[14] | + | - | + | +/- | Proximal > Distal | Systemic | BL or UL | Sudden | PCR of CSF | PCR of CSF | Asymmetric paralysis following a flu-like syndrome |
| Transverse myelitis[15] | + | + | + | + | Proximal > Distal | Systemic | BL or UL | Sudden | MRI & Lumbar puncture | MRI | Sensory level; history of viral or autoimmune disease |
| Multiple sclerosis exacerbation[16] | + | + | + | + | Generalized | Systemic | NL | Sudden | ↑CSF IgG (oligoclonal bands) | Clinical assessment and MRI | Blurry vision, urinary incontinence, fatigue |
| Amyotrophic lateral sclerosis[17] | + | - | - | - | Generalized | Systemic | BL | Insidious | Normal LP (to rule out DDx) | EMG (UMN + LMN signs) | Combined upper motor neuron (spasticity) and lower motor neuron (flaccidity) deficits |
| Inflammatory myopathy[18] | + | - | - | - | Proximal > Distal | Systemic | UL or BL | Insidious | Elevated CK & Aldolase | Muscle biopsy | Progressive proximal weakness in 3rd–5th decade, ± skin manifestations |
Epidemiology and Demographics
LEMS is rare, with an estimated incidence of approximately 0.17–0.6 cases per million per year and a prevalence of about 2.3–3.8 per million, far lower than myasthenia gravis; these figures are likely underestimates given frequent initial misdiagnosis.[3][2]
- Paraneoplastic (SCLC) LEMS: typical onset around age 60, male predominance (reflecting SCLC epidemiology).
- Non-tumor LEMS: broader age distribution with a smaller peak in younger adults and a larger peak around age 60; slight female predominance, as with other autoimmune diseases.[5]
Risk Factors
- Tobacco smoking — the dominant risk factor, largely through its association with SCLC.[19]
- HLA-B8-DR3 haplotype — associated with non-tumor LEMS.
- Personal or family history of autoimmune disease — associated with non-tumor LEMS.
Screening
A new LEMS diagnosis is a clinical warning sign for SCLC and mandates rigorous oncologic screening and surveillance.[2] SCLC is detected within 12 months in over 95% of paraneoplastic patients using intensive screening. The validated DELTA-P score — age at onset, smoking status at onset, bulbar involvement, weight loss, erectile dysfunction, and Karnofsky performance status — stratifies SCLC risk at diagnosis; weight loss ≥5%, tobacco use at onset, and age ≥50 were the independent predictors in prospective validation.[19][20] Chest CT is the first-line imaging modality; FDG-PET is used when initial imaging is negative, with periodic re-screening for up to two years.
Natural History, Complications, and Prognosis
Weakness is typically insidious and progressive. Possible complications include:
- Respiratory failure and difficulty breathing
- Dysphagia with aspiration risk
- Infections, including pneumonia
- Falls and injuries from weakness and impaired coordination
Prognosis diverges by subtype. Non-tumor LEMS carries a near-normal life expectancy, though complete remission is uncommon. In SCLC-LEMS, tumor progression determines survival, but outcomes are paradoxically better than SCLC without LEMS (median survival ~17 vs ~7 months in one registry comparison), likely reflecting earlier cancer detection and antitumor immunity.[20]
History and Symptoms
- Proximal muscle weakness, leg-predominant, usually the first symptom (~80%), causing difficulty rising from a chair, climbing stairs, and lifting.
- Autonomic symptoms — dry mouth (most common), orthostatic intolerance, constipation, and erectile dysfunction.
- Bulbar symptoms — mild dysphagia or dysarthria; ptosis/diplopia may occur but isolated ocular involvement is rare.
- Characteristic transient improvement of strength after brief exercise (the "warm-up" phenomenon).[5][4]
Physical Examination
- Proximal, symmetric weakness, legs greater than arms.
- Reduced or absent deep tendon reflexes, which may transiently reappear or strengthen after sustained contraction (post-activation facilitation).
- Autonomic signs (dry mucous membranes, orthostatic changes).[5]
Laboratory Findings
- Anti–P/Q-type VGCC antibodies — present in ~85–95% of patients; a negative result does not exclude LEMS (seronegative cases occur).
- Anti-SOX1 antibodies — favor an underlying SCLC.[3][4]
Other Diagnostic Studies
Electrodiagnostic testing is central:[5]
- Repetitive nerve stimulation (RNS) — low baseline compound muscle action potential (CMAP), a decrement (>10%) at low frequency (2–5 Hz), and a large increment (>60–100%) after high-frequency stimulation or brief maximal exercise (post-exercise facilitation).
- Single-fiber EMG (SFEMG) — highly sensitive, showing increased jitter and blocking that improve at higher firing rates.
Medical Therapy
Management combines symptomatic therapy, immunotherapy, and treatment of any underlying tumor.[21]
- Symptomatic therapy — amifampridine (3,4-diaminopyridine) is first-line and FDA-approved for LEMS in adults and children ≥6 years; it is a broad-spectrum potassium-channel blocker thought to prolong presynaptic depolarization and enhance acetylcholine release, though the FDA label notes the precise mechanism has not been fully elucidated. Pyridostigmine may be added as an adjunct.[22][23]
- Immunotherapy — for inadequate response or flares: prednisone plus azathioprine, IVIG, or plasma exchange.[21][5]
Surgery
There is no direct surgical therapy for LEMS itself. When paraneoplastic LEMS is identified, treatment of the underlying SCLC (chemotherapy, radiation, and/or resection per oncologic staging) takes priority and often improves the neurologic syndrome.[24]
Prevention
There are no established primary preventive measures beyond smoking cessation, which reduces SCLC risk. Secondary prevention centers on ongoing tumor surveillance after diagnosis and on immunotherapy to limit disability and relapse.[19][20]
References
- ↑ 1.0 1.1 1.2 Huijbers MG, Marx A, Plomp JJ, et al. Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022.
- ↑ 2.0 2.1 2.2 2.3 2.4 Schoser B, Eymard B, Datt J, Mantegazza R. Lambert-Eaton myasthenic syndrome (LEMS): a rare autoimmune presynaptic disorder often associated with cancer. J Neurol. 2017.
- ↑ 3.0 3.1 3.2 3.3 3.4 Punga AR, Maddison P, Heckmann JM, Guptill JT, Evoli A. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022.
- ↑ 4.0 4.1 4.2 4.3 Zarhin D, Kolb H, Gadoth A. Gasping for strength. N Engl J Med. 2025.
- ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011.
- ↑ 6.0 6.1 Gilhus NE. Myasthenia gravis. N Engl J Med. 2016;375(26):2570-2581. PMID 28029925.
- ↑ Talukder RK, Sutradhar SR, Rahman KM, Uddin MJ, Akhter H. Guillain-Barre syndrome. Mymensingh Med J. 2011;20(4):748-56. PMID 22081202.
- ↑ Merino-Ramirez MA, Bolton CF. Review of the diagnostic challenges of Lambert-Eaton syndrome revealed through three case reports. Can J Neurol Sci. 2016;43(5):635-47. PMID 27412406.
- ↑ Ozono K. Diagnostic criteria for vitamin D-deficient rickets and hypocalcemia. Clin Calcium. 2016;26(2):215-22. PMID 26813501.
- ↑ Kamanyire R, Karalliedde L. Organophosphate toxicity and occupational exposure. Occup Med (Lond). 2004;54(2):69-75. PMID 15020723.
- ↑ Pecina CA. Tick paralysis. Semin Neurol. 2012;32(5):531-2. PMID 23677663.
- ↑ Bane V, Lehane M, Dikshit M, O'Riordan A, Furey A. Tetrodotoxin: chemistry, toxicity, source, distribution and detection. Toxins (Basel). 2014;6(2):693-755. PMID 24566728.
- ↑ Kuntzer T, Hirt L, Bogousslavsky J. Neuromuscular involvement and cerebrovascular accidents. Rev Med Suisse Romande. 1996;116(8):605-9. PMID 8848683.
- ↑ Laffont I, Julia M, Tiffreau V, Yelnik A, Herisson C, Pelissier J. Aging and sequelae of poliomyelitis. Ann Phys Rehabil Med. 2010;53(1):24-33. PMID 19944665.
- ↑ West TW. Transverse myelitis - a review of the presentation, diagnosis, and initial management. Discov Med. 2013;16(88):167-77. PMID 24099672.
- ↑ Filippi M, Preziosa P, Rocca MA. Multiple sclerosis. Handb Clin Neurol. 2016;135:399-423. PMID 27432676.
- ↑ Riva N, Agosta F, Lunetta C, Filippi M, Quattrini A. Recent advances in amyotrophic lateral sclerosis. J Neurol. 2016;263(6):1241-54. PMID 27025851.
- ↑ Michelle EH, Mammen AL. Myositis mimics. Curr Rheumatol Rep. 2015;17(10):63. PMID 26290112.
- ↑ 19.0 19.1 19.2 Maddison P, Lipka AF, Gozzard P, et al. Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort. Sci Rep. 2020.
- ↑ 20.0 20.1 20.2 Verschuuren JJ, Palace J, Murai H, et al. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022.
- ↑ 21.0 21.1 Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010.
- ↑ Firdapse (amifampridine) FDA prescribing information. 2024.
- ↑ Yoon CH, Owusu-Guha J, Smith A, Buschur P. Amifampridine for the management of Lambert-Eaton myasthenic syndrome: a new take on an old drug. Ann Pharmacother. 2020.
- ↑ Chen T. Clinical reasoning: a 68-year-old man with proximal weakness and seizures. Neurology. 2021.
Template:PNS diseases of the nervous system Template:WH Template:WikiDoc Sources